A large trial to evaluate the use of dual drug treatment for more than a year post-stenting has left the sector with little more clarity than when the study began.
“The safest and most effective duration of dual antiplatelet therapy … remains uncertain and must be individualized for each patient,” a New England Journal of Medicine Editorial concludes following the...